Skip to main content
SpringerLink
Log in

Editorial: Addressing Controversies in Pediatric Oncology

  • Symposium on Pediatric Oncology: Hemato-Oncology
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood. 2012;120:1165–74.

    Article  PubMed  CAS  Google Scholar 

  2. Nguyen K, Devidas M, Chang SC, La M, Raetz EA, Carroll WL, et al; Children’s Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children’s Oncology Group study. Leukemia. 2008;22:2142–50.

    Article  PubMed  CAS  Google Scholar 

  3. Magrath I, Shanta V, Advani S, Adde M, Arya LS, Banavali S, et al. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period. Eur J Cancer. 2005;41:1570–83.

    Article  PubMed  CAS  Google Scholar 

  4. Kulkarni KP, Marwaha RK, Trehan A, Bansal D. Survival outcome in childhood ALL: Experience from a tertiary care centre in North India. Pediatr Blood Cancer. 2009;53:168–73.

    Article  PubMed  CAS  Google Scholar 

  5. Jain S, Kapoor G. How to treat relapsed acute lymphoblastic leukemia: Transplant vs. conventional chemotherapy. Indian J Pediatr. 2013; doi:10.1007/s12098-013-1036-5. Epub ahead of print.

    Google Scholar 

  6. Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, et al. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia—long-term results of trial ALL-REZ BFM P95/96. Eur J Cancer. 2013;49:1346–55.

    Article  PubMed  CAS  Google Scholar 

  7. Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J, et al; Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic advances in childhood leukemia & lymphoma (TACL) study. Blood. 2012;120:285–90.

    Article  PubMed  CAS  Google Scholar 

  8. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia: Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thrombosis Res. 2003;111:125–31.

    Article  CAS  Google Scholar 

  9. Zia A, Chitlur M. Management of thrombotic complications in acute lymphoblastic leukemia. Indian J Pediatr. 2013; doi:10.1007/s12098-013-1158-9.

    PubMed  Google Scholar 

  10. Henry M, Savasan S. Controversies in the role of radiotherapy in the treatment of pediatric hodgkin lymphoma. Indian J Pediatr. 2013; doi:10.1007/s12098-013-1106-8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India

    Sameer Bakhshi & Bivas Biswas

Authors
  1. Sameer Bakhshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bivas Biswas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sameer Bakhshi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bakhshi, S., Biswas, B. Editorial: Addressing Controversies in Pediatric Oncology. Indian J Pediatr 80, 844–845 (2013). https://doi.org/10.1007/s12098-013-1190-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-013-1190-9

Keywords

Search

Navigation